ClinicalTrials.gg
CompletedNCT05897866HLSSMUpdated Jun 26, 2023

Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management (HSSM)

An interventional study of Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management in Shoulder Impingement Syndrome, Adhesive Capsulitis and Rotator Cuff Tear, sponsored by Issa, Abdulhamid Sayed, M.D.. Completed at 1 site in Syrian Arab Republic. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by Issa, Abdulhamid Sayed, M.D. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Sep 2020, registered May 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Sex
All
01

Study summary

Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management (HSSM) is a limited lateral approach to the shoulder arthroscopically guided. Which achieves less surgical trauma and smaller surgical incision than even in Mini Lateral Shoulder Approach (MLSA).

Read the detailed description

After making a full clinical, X-rays and MRI examinations of the shoulder, and finding Shoulder Impingement Syndrome, Adhesive Capsulitis, Rotator Cuff Tear, or Hill-Sachs lesion, we decide to manage the problem surgically We can survey the shoulder from the inside and determine the shape, size and the exact position of the defect by shoulder arthroscopy.

The patient is operated on under general anesthesia; shoulder arthroscopy can be performed in the lateral decubitus or beach chair position which is the basic shoulder arthroscopy (Beach Chair Patient Positioning).

After identifying the full characteristics of the lesion, we go for Mini Lateral Shoulder Approach (MLSA), as known as Second Sayed Issa's Approach.

02

Conditions studied

  • Shoulder Impingement Syndrome
  • Adhesive Capsulitis
  • Rotator Cuff Tear
  • Hill-Sachs Lesion
  • Frozen Shoulder
  • Tendinopathy

Keywords

  • Shoulder
  • Shoulder approach
  • Lateral Shoulder approach
  • Shoulder impingement syndrome
  • Rotator cuff tendinopathy
  • Adhesive capsulitis
  • Frozen shoulder syndrome
  • MLSA
  • Shoulder arthroscopy
  • Mini Lateral Shoulder Approach
  • Second Sayed Issa's Approach
  • Hill-sachs lesion
  • mini-incision release
  • Tendinopathy
  • arthroscopy
  • tendon injuries
03

In context

Shoulder Impingement Syndrome

320 studies on the registry are indexed under Shoulder Impingement Syndrome; 62 are open to participants now.

This study's enrollment of 44 is below the median of 54 across 271 interventional studies indexed under Shoulder Impingement Syndrome.

Browse Shoulder Impingement Syndrome studies →

Lead sponsor

Issa, Abdulhamid Sayed, M.D. is the lead sponsor of 5 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presented with Shoulder Impingement Syndrome to conservative treatment and local injection
  • Patients presented with Adhesive Capsulitis and Frozen Shoulder Syndrome refractory to conservative treatment and local steroid injection
  • Patients without femur head immigration on X-ray
  • Patients with injury for one month to six months maximum

Exclusion criteria

Exclusion Criteria:

  • Patients with femur head immigration on X-ray
  • Patients with injury for more than six months
  • Uncontrolled diabetes mellitus type 1 and 2
  • Patients with non controlled Vascular hypertension
  • Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant.
  • Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, , or treatment for acute congestive heart failure within 4 months prior to randomization
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Issa3

    Dr.A.Sayed Issa and his team

    Procedure: Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management

Interventions

  • ProcedureSayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management

    Using Arthroscopy and then Limited Opening by Mini Lateral Shoulder Approach (MLSA) for the shoulder surgery.

    Also known as: Sayed Issa's HSSM

06

What researchers measure

Primary outcomes

  1. Less open surgery trauma

    Directly going to the goal lesion with less expansion

    Time frame: 25 minutes to 45 minutes,

Secondary outcomes

  1. Smaller surgical incision than MLSA

    Directly going to the goal lesion

    Time frame: Less than 5 cm

07

Study locations

1 site
  • Dr. Abdulhamid Sayed Issa Clinic
    Aleppo, Syrian Arab Republic
08

References and documents

Related links

Individual participant data

Plan to share: Yes

Data sharing details ↗ · www.asayedissa.com

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05897866
Lead sponsor
Issa, Abdulhamid Sayed, M.D.
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
Sep 1, 2020
Primary completion
May 12, 2023
Completion
May 12, 2023
Last update
Jun 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion